Correlation between Molecular Subtypes and Clinical Features in Invasive Ductal Carcinoma of Breast
-
摘要: 目的 探讨乳腺浸润性导管癌不同分子亚型的分布，并分析各分子亚型与临床特征的关系。 方法 收集2006年1月-2011年6月明确诊断为乳腺浸润性导管癌病例100例，根据雌激素受体（ER）、孕激素受体（PR）、表皮生长因子受体-2（HER-2）的表达情况划分为四型，进一步分析不同分子亚型与浸润性导管癌临床特征的关系。 结果 100例中Luminal A型所占比例最大为65%，7%为Luminal B型, Triple Negative型占17%，Her-2(+)型占11%。各分子亚型乳腺浸润性导管癌患者发病年龄主要集中在40~59岁之间，占73%，Luminal A型发病年龄主要集中在40~49岁，而其他三型主要分布于50~59岁，四型在不同年龄组的分布上差异有统计学意义（P＜0.05）；Luminal A型淋巴转移发生率仅为30.1%，而Luminal B型与Her-2(+)型淋巴转移发生率较高，分别为71.4%及63.6%，各分子亚型的腋窝淋巴结转移率有显著差异（P＜0.05）；病理组织学分级Ⅰ级中Luminal A型所占比例最高，而Triple Negative型主要以Ⅲ级为主,差异具有统计学意义（P＜0.05）。 结论 乳腺浸润性导管癌各分子亚型分布差异具有统计学意义，各分子亚型与其临床特征关系密切。Abstract: Objective To investigate the distribution of different molecular subtypes of invasive ductal carcinoma of breast(IDC)，and analyze the correlation between molecular subtypes and clinical features. Methods A total of 100 patients with IDC from January 2006 to June 2011 were classified into four different subtypes according to estrogen receptor (ER), progestogen receptor (PR) and epidermal growth factor-2 (HER-2)，and analyze their relation to the clinical features of IDC. Results Among all 100 cases,Luminal A subtype was the majority (65％), triple negative was the second largest group(17% ), and Her-2 enriched and Luminal B type are the smallest groupes (17% and 7%, respectively). The ages of patients of IDC subtype were mainly between 40 and 59 (73%).The ages of patients of Luminal A subtype were mainly between 40 and 49.The ages of the patients of the other three molecular subtypes were mainly between 50 and 59(P<0.05) . The distributions in different age groups had statistic significance (P<0.05). There were more lymph nodes metastasis in Luminal B(71.4%) and HER-2 enriched (63.6%) groups(P＜0.05) than in Luminal A group(30.1%). The axillary lymph nodes metastasis rates of different molecular subtypes varied significantly (P<0.05). As for histopathologic grading,Luminal A patients were mainly gradeⅠ, and most Triple Negative patients were grade Ⅲ（P＜0.05）. The difference had statistic significance (P<0.05). Conclusion The distributions of different molecular subtypes of IDC has significant difference．The molecular subtypes are related to the clinical features of IDC.
-
Key words:
- Invasive ductal carcinoma /
- Molecular subtype /
- Clinical feature
-
-
[1] [1]Jemal A,Siegel R,Xu J,et al.Cancer statistics,2010[J].CA Cancer J Clin,2010,60(5):277-300. [2] Carlson RW,Allred DC,Anderson BO,et al. Invasive breast cancer[J].J Natl Compr Canc Netw,2011,9(2):136-222. [3] van de Rijn M,Perou CM,Tibshirani R,et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome[J]. Am J Pathol,2002, 161 (6) : 1991-6. [4] Yu K,Lee CH,Tan PH,et al. Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations[J]. Clin Cancer Res,2004,10(16): 5508-17. [5] Group of guideline of HER-2 detection in breast cancer.Guideline of HER-2 detection in breast cancer[J].Zhonghua Bing Li Xue Za Zhi,2006, 35(10):631-3.[《乳腺癌HER-2检测指南》编写组．乳腺癌 HER-2检测指南[J].中华病理学杂志,2006,35(10):631-3.] [6] Perou CM，Serlie T，Eisen MB，et al．Molecular portraits of human breast tumours[J]．Nature, 2000,406 (6797):747-52． [7] Calza S,Hall P,Auer G,et al.Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients[J].Breast Cancer Res,2006,8(4):R34． [8] Nielsen TO,Hsu FD,Jensen K,et al.Immunohistochemical and clinical characterization of the basal-like subtype of imvasive breast cancer[J].Clin Cancer Res,2004,10(16):5367-74． [9] Carey LA，Perou CM，Livasy CA，et al. Race，breast cancer subtypes，and survival in the Carolina Breast Cancer Study[J]. JAMA,2006,295 (21):2492-502. [10] Chen LY,Chen HF,Fu N,et al.The clinical featuer of different molecular subtypes of 218 invasive breast cancer cases[J].Xian Dai Zhong Liu Yi Xue,2007,15(8)：1094-7.[陈莉颖,陈红风,付娜,等.218例不同分子亚型浸润性乳腺癌患者的临床特征[J].现代肿瘤医学,2007,15(8):1094-7.] [11] Zhang HM,Zhang BN,Xuan LX,et al. Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes[J].Zhonghua Zhong Liu Za Zhi,2009,31(6):447-51.[张慧明,张保宁,宣立学,等.可手术的不同分子亚型乳腺癌的临床特征和生存分析[J].中华肿瘤杂志,2009,31(6):447-51.]
计量
- 文章访问数: 3839
- HTML全文浏览量: 24
- PDF下载量: 382
下载:
